Tech

UniQure stock slides 40% after FDA signals AMT-130 data can't support filing

The FDA signaled that Phase 1/2 AMT-130 data won’t suffice for a Huntington’s disease BLA, triggering a ~40% premarket slide and prompting uniQure to seek a Type B meeting in 2026 to map a new path forward.

📅 March 02, 2026
⏱️ 2 min read
UniQure stock slides 40% after FDA signals AMT-130 data can't support filing

Key Takeaways

  • FDA advised against using Phase 1/2 AMT-130 data as primary evidence for a BLA for Huntington’s disease.
  • FDA strongly recommended a prospective, randomized, double-blind, sham surgery–controlled trial.
  • uniQure plans a Type B meeting in Q2 2026 to discuss submission pathway.
  • AMT-191 data in February show dose-dependent α-Gal A activity across three dose levels.
  • Company cash and equivalents near $622.5 million as of 12/31/2025, funding operations into 2H2029; premarket price fell to about $8.85.

People Involved

  • Matt Kapusta CEO of uniQure

Entities Involved

  • uniQure N.V. Biotech company developing gene therapies (AMT-130, AMT-191, AMT-260)
  • FDA - U.S. Food and Drug Administration Regulatory authority signaling data requirements for BLA submissions

MarketMoodz Analysis

This regulatory setback shifts the trajectory for uniQure’s core Huntington’s program AMT-130, increasing the regulatory lead time and potentially delaying a BLA submission. For investors, the shift from relying on early-phase data to needing prospectively gathered trial data raises funding and valuation risks, particularly for a cash-constrained biotech with near-term catalysts tied to multiple clinical readouts.

Historically, gene-therapy programs face intense regulatory scrutiny: agencies push for robust, randomized trials to demonstrate clinical benefit and safety before approval. The market’s negative reaction to AMT-130 signals reflects a broader risk-off stance in biotech small caps when data packages don’t align with regulatory expectations. Watch for AMT-191 and AMT-260 data in H1 2026, any strategic moves (financing or partnerships), and the FDA’s feedback from the Type B meeting to gauge the path forward.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial